Cargando…
Engineered a dual-targeting HA-TPP/A nanoparticle for combination therapy against KRAS-TP53 co-mutation in gastrointestinal cancers
KRAS-TP53 co-mutation is strongly associated with poor prognosis and high malignancy in gastrointestinal cancers. Therefore, a novel approach to oncotherapy may lie in combination therapy targeting both KRAS and TP53. Herein, we present a novel self-assembled nanoparticle (HA-TPP/A) that are functio...
Autores principales: | Mei, Yong, Qin, Xiaohua, Yang, Zhenyu, Song, Shiyao, Liu, Xiaoting, Wu, Chong, Qian, Jieying, Huang, Xiaowan, Zhang, Yunjiao, He, Weiling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590736/ https://www.ncbi.nlm.nih.gov/pubmed/37876556 http://dx.doi.org/10.1016/j.bioactmat.2023.10.003 |
Ejemplares similares
-
KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009) -
Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023) -
Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles
por: Zhang, Hao, et al.
Publicado: (2023) -
Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014) -
TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
por: Guo, Chunguang, et al.
Publicado: (2022)